Who
Andreas Busch
Chief Innovation Officer
Company insider
Files Form 4 as: Chief Innovation Officer, Absci; Chief Scientific Officer, Cyclerion Therapeutics.
In numbers
- Trades disclosed
- 26
- Buys
- 4
- Sells
- 0
- Bought
- $1.2M
- Sold
- $0
- Companies
- 2
- Companies where not an officer
- 0
- First trade
- 29 Apr 2019
- Last trade
- 12 Mar 2026
- Last filed
- 16 Mar 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 12 Mar 2026filed 16 Mar 2026 | ABSI AbsciLife-science tools | SEC FORM 4 Bought | $229K100,000 at $2.29 | filing |
| 12 Mar 2026filed 16 Mar 2026 | ABSI AbsciLife-science tools | SEC FORM 4 Bought | $229K100,000 at $2.29 | filing |
| 3 Mar 2026filed 4 Mar 2026 | ABSI AbsciLife-science tools | SEC FORM 4 Code F | $3,5201,257 at $2.80 | filing |
| 3 Mar 2026filed 4 Mar 2026 | ABSI AbsciLife-science tools | SEC FORM 4 Code F | $3,5201,257 at $2.80 | filing |
| 3 Feb 2026filed 4 Feb 2026 | ABSI AbsciLife-science tools | SEC FORM 4 Code F | $4,3921,469 at $2.99 | filing |
| 3 Feb 2026filed 4 Feb 2026 | ABSI AbsciLife-science tools | SEC FORM 4 Code F | $4,3921,469 at $2.99 | filing |
| 14 Oct 2025filed 14 Oct 2025 | ABSI AbsciLife-science tools | SEC FORM 4 Code F | $11K3,092 at $3.68 | filing |
| 28 Jul 2025filed 29 Jul 2025 | ABSI AbsciLife-science tools | SEC FORM 4 Bought | $152K50,000 at $3.04 | filing |
| 3 Mar 2025filed 4 Mar 2025 | ABSI Abscioption or derivative · Life-science tools | SEC FORM 4 Code A | —93,700 at $0.00 | filing |
| 3 Mar 2025filed 4 Mar 2025 | ABSI AbsciLife-science tools | SEC FORM 4 Code A | —23,700 at $0.00 | filing |
| 1 Feb 2025filed 4 Feb 2025 | ABSI AbsciLife-science tools | SEC FORM 4 Code F | $5,4501,469 at $3.71 | filing |
| 12 Oct 2024filed 16 Oct 2024 | ABSI AbsciLife-science tools | SEC FORM 4 Code F | $13K3,092 at $4.07 | filing |
| 1 Feb 2024filed 5 Feb 2024 | ABSI Abscioption or derivative · Life-science tools | SEC FORM 4 Code A | —349,625 at $0.00 | filing |
| 1 Feb 2024filed 5 Feb 2024 | ABSI AbsciLife-science tools | SEC FORM 4 Code A | —83,125 at $0.00 | filing |
| 12 Oct 2023filed 16 Oct 2023 | ABSI AbsciLife-science tools | SEC FORM 4 Code A | —175,000 at $0.00 | filing |
| 1 Mar 2023filed 3 Mar 2023 | ABSI Abscioption or derivative · Life-science tools | SEC FORM 4 Code A | —550,000 at $0.00 | filing |
| 3 Oct 2022filed 5 Oct 2022 | ABSI Abscioption or derivative · Life-science tools | SEC FORM 4 Code A | —2,000,009 at $0.00 | filing |
| 8 Jun 2022filed 10 Jun 2022 | ABSI Abscioption or derivative · Life-science tools | SEC FORM 4 Code A | —4,783 at $0.00 | filing |
| 17 Mar 2022filed 21 Mar 2022 | ABSI Abscioption or derivative · Life-science tools | SEC FORM 4 Code A | —45,180 at $0.00 | filing |
| 20 Jan 2022filed 24 Jan 2022 | Cyclerion Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —135,000 at $0.00 | filing |
News
Comparing Mereo BioPharma Group (NASDAQ:MREO) and Absci (NASDAQ:ABSI)ABSI · themarketsdaily.com · 24 Oct 2026Absci (NASDAQ:ABSI) Given New $20.00 Price Target at KeyCorpABSI · themarketsdaily.com · 16 Oct 2026Absci (NASDAQ:ABSI) Price Target Raised to $15.00ABSI · dailypolitical.com · 15 Oct 2026
0 headlines in the last 90 days name Andreas Busch; 3 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.